Industry
U.S. commission warns China could gain from biopharma licensing deals
The commission warned that U.S.-China drug licensing deals could transfer expertise to Chinese partners and leave the U.S. more dependent on China for medicines.

A congressional commission warned that U.S.-China pharmaceutical licensing deals could transfer expertise to Chinese partners and erode U.S. biotech research and development. It urged U.S. lawmakers to act quickly to prevent overdependence on China that could leave American patients vulnerable to supply chain weaponization, Healthcare Dive and BioPharma Dive reported.
The commission said many deals are based on preclinical research and are rising in value. It warned that repeat collaborations and more elaborate deal structures could pass along knowledge about drug development, commercialization and U.S. regulatory best practices. China’s goal is to produce a quarter of the world’s “first-in-class drugs” by 2030, the reports said. The 11-member commission, formed under 2022 defense appropriations legislation to study biotech competition, said deals are starting to favor Chinese startups.


